Neocart- Failed
Novocart3d - By aesculap biologics, owned by braun. Already in the orthopedic market. Approved in europe. Only investigational use in the US, in phase 3 trials. Primary study ends May 2019. The actual procedure is somewhere inbetween Carticel and MACI. It requires suturing vs gluing. It does have braun behind it which is a big name but the actual procedure seems to favor MACI.
Hylagraft C - This was pulled from the european market in 2013 because they couldn’t provide enough data to keep it on the market. They are trying again now with hyalofast, which is a “non-woven, single-step, off-the-shelf, biodegradable HA-based scaffold for hyaline-like cartilage regeneration to treat cartilage injuries and defects” Primary endpoint results in december 2020. Main positive with them is this is a single stage procedure unlike MACI.
Cartipatch - study terminated
Chondrosphere - to my knowledge and brief search is approved in the EU but has no ongoing trials in the US.
Revaflex - ISTO’s website says they are still recruiting for their phase 3 trial. Clinicaltrials.gov says the study is terminated. I’d believe clinicaltrials.gov.
The only one that looks like a potential issue to me is Hylagraft c, which is now called hylafast. We have a couple years before that one is an issue. They need to complete their phase 3 study and then submit data to the FDA. One to watch, but not worry about right now. Novocart is the next one up, they don’t seem to have any advantages over MACI, only disadvantages other than they are owned by Braun.
Best,
Ethan